1. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Issue 8 (25th June 2020) Authors: Ngoi, Natalie YL; Heong, Valerie; Ow, Samuel; Chay, Wen Yee; Kim, Hee Seung; Choi, Chel Hun; Goss, Geraldine; Goh, Jeffrey C; Tai, Bee Choo; Lim, Diana GZ; Kaliaperumal, Nivashini; Au, Veonice B; Connolly, John E; Kim, Jae-Weon; Friedlander, Michael; Kim, Kidong; Tan, David SP Journal: International journal of gynecological cancer Issue: Volume 30:Issue 8(2020) Page Start: 1239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multicenter phase II randomized trial of durvalumab (MEDI‐4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Issue 8 (August 2020) Authors: Ngoi, Natalie YL; Heong, Valerie; Ow, Samuel; Chay, Wen Yee; Kim, Hee Seung; Choi, Chel Hun; Goss, Geraldine; Goh, Jeffrey C; Tai, Bee Choo; Lim, Diana GZ; Kaliaperumal, Nivashini; Au, Veonice B; Connolly, John E; Kim, Jae‐Weon; Friedlander, Michael; Kim, Kidong; Tan, David SP Journal: International journal of gynecological cancer Issue: Volume 30:Issue 8(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗